[go: up one dir, main page]

ES2531646T3 - Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno - Google Patents

Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno Download PDF

Info

Publication number
ES2531646T3
ES2531646T3 ES11717561.2T ES11717561T ES2531646T3 ES 2531646 T3 ES2531646 T3 ES 2531646T3 ES 11717561 T ES11717561 T ES 11717561T ES 2531646 T3 ES2531646 T3 ES 2531646T3
Authority
ES
Spain
Prior art keywords
weight
vol
progestogen
low oil
emulsion compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11717561.2T
Other languages
English (en)
Inventor
Laura Pickersgill
Eva-Maria Di Hoiser
Georg Achleitner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins Healthcare Luxembourg SARL
Original Assignee
Besins Healthcare Luxembourg SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxembourg SARL filed Critical Besins Healthcare Luxembourg SARL
Application granted granted Critical
Publication of ES2531646T3 publication Critical patent/ES2531646T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición de emulsión aceite en agua farmacéutica, estéril, lista para su uso, para administración por vía parenteral que comprende: * 0.015 a 0.5% en peso/vol., preferiblemente de 0.05 a 0.4% en peso/vol. de progesterona; * 0.5 a 10% en peso/vo l. de aceite, en donde el aceite comprende al menos 85% en peso/peso de triglicéridos; * 0.0425 a 4.1% en peso/vol., preferiblemente de 0.064 a 3.4% en peso/vol. de fosfolípido; * 80 a 99.4% en peso/vol. de medio acuoso; en donde la composición tiene una osmolalidad en el intervalo de 200-1000 mOsm/kg, y en donde la emulsión contiene no más de 1.2% en peso/peso de polietilenglicol 15-hidroxiestearato.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
-
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
------
---
imagen27
imagen28
------
---
imagen29
imagen30
imagen31
EJEMPLO 4B
NO ESTÉRIL ESTERILIZADO 1x ESTERILIZADO 2x ESTERILIZADO 3x 3 SEMANAS, 60°C 4 SEMANAS, 60°C
MASTERSIZER UNIFORMIDAD
0.587 0.587 0.590 0.589 0.590 0.583
MASTERSIZER d(0,5) [M]
0.176 0.176 0.174 0.175 0.174 0.179
ACCUSIZER [%]
0.02 0.02 0.03 0.02 0.02 0.02
VALOR DE PH
8.3 7.9 7.6 7.4 6.4 6.5
EJEMPLO 4C
NO ESTÉRIL ESTERILIZADO 1x ESTERILIZADO 2x ESTERILIZADO 3x 3 SEMANAS, 60°C 4 SEMANAS, 60°C
Apariencia
BLANCO,HOMOGÉNEO BLANCO,HOMOGÉNEO BLANCO,HOMOGÉNEO BLANCO,HOMOGÉNEO BLANCO,HOMOGÉNEO BLANCO,HOMOGÉNEO
CONTROL VISUAL
SIN PARTÍCULAS SIN PARTÍCULAS SIN PARTÍCULAS SIN PARTÍCULAS SIN PARTÍCULAS SIN PARTÍCULAS
MASTERSIZER D[4,3] [M]
0.228 0.229 0.228 0.229 0.232 0.227
MASTERSIZER SPAN
2.065 2.059 2.069 2.066 2.041 2.069
MASTERSIZER UNIFORMIDAD
0.633 0.632 0.635 0.635 0.628 0.637
MASTERSIZER d(0.5) [M]
0.181 0.182 0.180 0.182 0.185 0.80
ACCUSIZER [%] (USP 729)
0.01 0.01 0.03 0.01 0.02 0.02
VALOR DE PH
8.2 8.0 7.8 7.6 7.2 6.8
imagen32
imagen33
imagen34

Claims (1)

  1. imagen1
    imagen2
ES11717561.2T 2010-04-26 2011-04-26 Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno Active ES2531646T3 (es)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US32796810P 2010-04-26 2010-04-26
US32795910P 2010-04-26 2010-04-26
US32796310P 2010-04-26 2010-04-26
EP10161032 2010-04-26
US327968P 2010-04-26
US327963P 2010-04-26
EP10161029 2010-04-26
US327959P 2010-04-26
EP10161029 2010-04-26
EP10161032 2010-04-26
EP10161034 2010-04-26
EP10161034 2010-04-26
US201061424402P 2010-12-17 2010-12-17
US201061424411P 2010-12-17 2010-12-17
US201061424407P 2010-12-17 2010-12-17
EP10195764 2010-12-17
EP10195760 2010-12-17
EP10195760 2010-12-17
US424411P 2010-12-17
EP10195766 2010-12-17
EP10195764 2010-12-17
US424407P 2010-12-17
EP10195766 2010-12-17
US424402P 2010-12-17
PCT/EP2011/056548 WO2011134944A2 (en) 2010-04-26 2011-04-26 Low-oil pharmaceutical emulsion compositions comprising progestogen

Publications (1)

Publication Number Publication Date
ES2531646T3 true ES2531646T3 (es) 2015-03-18

Family

ID=44001967

Family Applications (4)

Application Number Title Priority Date Filing Date
ES11717561.2T Active ES2531646T3 (es) 2010-04-26 2011-04-26 Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
ES14176970.3T Active ES2576190T3 (es) 2010-04-26 2011-04-26 Composiciones farmacéuticas de emulsión que comprenden progestógeno
ES14196653.1T Active ES2606585T3 (es) 2010-04-26 2011-04-26 Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
ES11716893.0T Active ES2514690T3 (es) 2010-04-26 2011-04-26 Composiciones farmacéuticas de emulsión que comprenden progestógeno

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES14176970.3T Active ES2576190T3 (es) 2010-04-26 2011-04-26 Composiciones farmacéuticas de emulsión que comprenden progestógeno
ES14196653.1T Active ES2606585T3 (es) 2010-04-26 2011-04-26 Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
ES11716893.0T Active ES2514690T3 (es) 2010-04-26 2011-04-26 Composiciones farmacéuticas de emulsión que comprenden progestógeno

Country Status (22)

Country Link
US (4) US8476252B2 (es)
EP (4) EP2801353B1 (es)
JP (1) JP5886273B2 (es)
KR (1) KR101822680B1 (es)
CN (2) CN102946865B (es)
AR (1) AR081542A1 (es)
AU (1) AU2011246527B2 (es)
BR (1) BR112012027279B1 (es)
CA (2) CA2797253C (es)
EA (1) EA022460B1 (es)
ES (4) ES2531646T3 (es)
GE (1) GEP20166457B (es)
IL (2) IL222710A (es)
MX (1) MX2012012491A (es)
MY (1) MY156858A (es)
NZ (1) NZ603176A (es)
PH (1) PH12012502120B1 (es)
PL (1) PL2563335T3 (es)
PT (1) PT2563335E (es)
SG (1) SG185025A1 (es)
TW (1) TW201138782A (es)
WO (2) WO2011134944A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
WO2013127727A1 (en) 2012-02-29 2013-09-06 B. Braun Melsungen Ag Hormone containing emulsion comprising krill phospholipids
TWI651098B (zh) * 2012-02-29 2019-02-21 Ｂ 柏藍麥桑根公司 含荷爾蒙的乳劑
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105263475A (zh) * 2013-03-15 2016-01-20 制药创源有限公司 雷公藤甲素静脉注射乳剂用作免疫调制剂和抗癌药
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721105A (en) * 2013-12-06 2022-04-29 Broad Inst Inc Formulations for neoplasia vaccines
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
JP2017526794A (ja) * 2014-09-12 2017-09-14 ドレクセル ユニバーシティ グラフト化トリグリセリドを使用した酸無水物硬化熱硬化性エポキシポリマーの強化
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
JP6814148B2 (ja) * 2015-03-31 2021-01-13 フレゼニウス カービ ドイチュラント ゲーエムベーハー 非経口投与用のエマルション
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106074383B (zh) * 2016-07-27 2019-03-08 武汉科福新药有限责任公司 孕激素药物脂微球注射液及其制备方法
US20180207264A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force Porcine immune modulation model
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3893847A4 (en) * 2018-12-10 2022-11-02 Halo Science LLC STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS
US20230054162A1 (en) 2019-12-20 2023-02-23 Fresenius Kabi Austria Gmbh Methods for producing oil-in-water emulsions
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3878434A1 (en) * 2020-03-12 2021-09-15 Lipoid GmbH Sunflower phospholipid composition containing phosphatidylcholine
WO2023034317A1 (en) * 2021-08-30 2023-03-09 Premier Nutrition Company, Llc Sleep-inducing beverage composition, its method of production and the method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60258110A (ja) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
IL89856A (en) 1989-04-05 1993-05-13 Yissum Res Dev Co Medical emulsions for liphophilic drugs containing a medium-chain triglyceride oil as a carrier
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
SE9403389D0 (sv) 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
EA007070B1 (ru) * 1999-07-22 2006-06-30 Авентис Фармасьютиклс, Инк. Пресервированные фармацевтические составы
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6327968B1 (en) 2000-03-17 2001-12-11 Pizza Hut, Inc. System and method for producing par-baked pizza crusts
EP1488785A1 (de) * 2003-06-18 2004-12-22 B. Braun Melsungen Ag Ölemulsion zur postnatalen Hormonsubstitution
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
RS52471B (sr) 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen

Also Published As

Publication number Publication date
PH12012502120B1 (en) 2018-01-12
CA2797141A1 (en) 2011-11-03
US8476252B2 (en) 2013-07-02
US20110262494A1 (en) 2011-10-27
CA2797253C (en) 2019-02-05
AU2011246527A1 (en) 2012-11-15
EP2563335B1 (en) 2014-12-17
EP2563334B1 (en) 2014-07-16
PT2563335E (pt) 2015-03-31
ES2514690T3 (es) 2014-10-28
EA201291108A1 (ru) 2013-04-30
EP2857042A1 (en) 2015-04-08
MY156858A (en) 2016-04-15
US20140335133A1 (en) 2014-11-13
IL222738A (en) 2015-11-30
WO2011134937A2 (en) 2011-11-03
WO2011134937A3 (en) 2012-02-02
EP2801353A1 (en) 2014-11-12
BR112012027279B1 (pt) 2020-12-29
PH12012502120A1 (en) 2013-02-04
CA2797253A1 (en) 2011-11-03
CN102946864A (zh) 2013-02-27
ES2576190T3 (es) 2016-07-06
EP2563334A2 (en) 2013-03-06
CN102946865B (zh) 2016-06-22
US20110262495A1 (en) 2011-10-27
AR081542A1 (es) 2012-10-03
IL222710A (en) 2015-11-30
EP2801353B1 (en) 2016-03-30
TW201138782A (en) 2011-11-16
CN102946865A (zh) 2013-02-27
US20140147474A1 (en) 2014-05-29
AU2011246527B2 (en) 2016-09-15
EA022460B1 (ru) 2016-01-29
JP2013525402A (ja) 2013-06-20
US8765149B2 (en) 2014-07-01
CA2797141C (en) 2018-05-15
EP2563335A2 (en) 2013-03-06
HK1181998A1 (en) 2013-11-22
MX2012012491A (es) 2013-02-15
WO2011134944A2 (en) 2011-11-03
WO2011134944A3 (en) 2012-02-09
IL222710A0 (en) 2012-12-31
EP2857042B1 (en) 2016-08-31
GEP20166457B (en) 2016-04-11
NZ603176A (en) 2014-05-30
KR20130069638A (ko) 2013-06-26
KR101822680B1 (ko) 2018-01-26
US9572818B2 (en) 2017-02-21
BR112012027279A2 (pt) 2018-05-15
ES2606585T3 (es) 2017-03-24
PL2563335T3 (pl) 2015-05-29
JP5886273B2 (ja) 2016-03-16
SG185025A1 (en) 2012-11-29
IL222738A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
PH12016500100B1 (en) Self-emulsifying composition of omega3 fatty acid
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
BR112014030820A2 (pt) formulação de anticorpos
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
AR077338A1 (es) Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion.
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
UA111825C2 (uk) Стабілізований препарат, що містить антитіло проти ngf
RU2020108079A (ru) Инъекционная фармацевтическая композиция, содержащая мелоксикам, и способ ее получения
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
BR112014027116A2 (pt) formulação de anticorpo
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
BRPI0919753B8 (pt) forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CY1110037T1 (el) Σκευασματα για βενζιμιδαζολυλ πυριδυλ αιθερες
AR081535A1 (es) Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso
BR112015005995A2 (pt) formulações líquidas de apixaban
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.